Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
International Journal of Technology Assessment in Health Care
|
June 5, 2004
Pharmaceutical industry's perspective on health technology assessment
Mickael Lothgren, Mark Ratcliffe
Vaccine
|
July 17, 2007
Do we fully understand the economic value of vaccines?
Michael Drummond, Catherine Chevat, Mickael Lothgren
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2022
Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology
Adrian Towse, Mickael Lothgren, Lotte Steuten, et al.
Applied Health Economics and Health Policy
|
April 23, 2009
A pharmacoeconomic analysis of compliance gains on antipsychotic medications
Joep Damen, Per-Olof Thuresson, Bart Heeg, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
February 25, 2015
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2024
Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies
Lotte Steuten, Mickael Lothgren, Andrew Bruce, et al.
Journal of Opioid Management
|
October 1, 2011
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective
A Brett Hauber, Jochen Fleischmann, Mickael Lothgren, et al.
Clinical Cardiology
|
April 20, 2016
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Shravanthi R Gandra, Guillermo Villa, Gregg C Fonarow, et al.
Oncology and Therapy
|
November 14, 2025
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy
Marc-Oliver Grimm, Emma Karim, Venediktos Kapetanakis, et al.
Journal of Medical Economics
|
May 10, 2017
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
Joaquim Cristino, Jíndřich Finek, Petra Jandova, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
International Journal of Technology Assessment in Health Care
|
June 5, 2004
Pharmaceutical industry's perspective on health technology assessment
Mickael Lothgren, Mark Ratcliffe
Vaccine
|
July 17, 2007
Do we fully understand the economic value of vaccines?
Michael Drummond, Catherine Chevat, Mickael Lothgren
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2022
Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology
Adrian Towse, Mickael Lothgren, Lotte Steuten, et al.
Applied Health Economics and Health Policy
|
April 23, 2009
A pharmacoeconomic analysis of compliance gains on antipsychotic medications
Joep Damen, Per-Olof Thuresson, Bart Heeg, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
February 25, 2015
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2024
Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies
Lotte Steuten, Mickael Lothgren, Andrew Bruce, et al.
Journal of Opioid Management
|
October 1, 2011
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective
A Brett Hauber, Jochen Fleischmann, Mickael Lothgren, et al.
Clinical Cardiology
|
April 20, 2016
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Shravanthi R Gandra, Guillermo Villa, Gregg C Fonarow, et al.
Oncology and Therapy
|
November 14, 2025
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy
Marc-Oliver Grimm, Emma Karim, Venediktos Kapetanakis, et al.
Journal of Medical Economics
|
May 10, 2017
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
Joaquim Cristino, Jíndřich Finek, Petra Jandova, et al.
Page
of 2